Raisio (RAIKV) Q4 2025 earnings summary

Executive summary

• Net sales for 2025 decreased by 1.1% year-over-year to €224.2 million, while comparable EBIT rose by 21.6% to €40.7 million, reflecting improved operational efficiency and strategic focus on core brands.

• Profitability improved in 2025, laying a foundation for future growth despite a slight decline in net sales year-over-year.

• Strategic focus on core brands, divestment of the plant protein business, and organizational restructuring supported operational efficiency.

• The Elovena® brand grew strongly in Finland, up 14% in Q4 year-over-year, and Benecol® sales increased slightly, though UK sales were impacted by unfavorable exchange rates.

• The company maintained a strong balance sheet, enabling flexibility for future investments and growth.

Financial highlights

• Comparable EBIT for 2025 rose by 21.6% to €40.7 million, and comparable EBITDA increased by 13.3% to €37.8 million.

• Net sales for 2025 were €224.2 million, down 1.1% year-over-year; Q4 net sales were €55.2 million, up 0.6%.

• Earnings per share were €0.15, up from €0.11 year-over-year.

• Cash flow from operations after financial items and taxes was €27.5 million, down from €39.3 million.

• Board proposes a dividend of €0.15 per share.

Outlook and guidance

• Net sales and comparable EBIT for continuing operations are projected to increase in 2026 compared to 2025.

• The Board proposes a dividend of €0.15 per share, maintaining a policy to distribute 50-100% of EPS as dividends.